Medication and atypical brain maturation in psychosis are associated with long-term cognitive decline and symptom progression

Claudio Alemán-Morillo[1], Natalia García-San-Martín[1], Richard AI Bethlehem[2], Lena Dorfschmidt[3,4], María Alemany-Navarro[5], Patricia Segura[1], Alessia Pasquini[1], Manuel Muñoz-Caracuel[5], Manuel Canal Rivero[5], Jakob Seidlitz[3,4,7,8], Rosa Ayesa-Arriola[9], Javier Vázquez-Bourgon[9], John Suckling[10], Miguel Ruiz-Veguilla[6], Benedicto Crespo-Facorro[6], Rafael Romero-García[1,10,11].

Author affiliations:

[1]Department of Medical Physiology and Biophysics, University of Seville; Seville, Spain.

[2]Department of Psychology, University of Cambridge; Cambridge, UK.

[3]Department of Child and Adolescent Psychiatry and Behavioral Science, The Children's Hospital of Philadelphia; Philadelphia, PA, USA.

[4]Lifespan Brain Institute, The Children's Hospital of Philadelphia and Penn Medicine; Philadelphia, PA, USA.

[5]Translational Psychiatry Group, Instituto de Biomedicina de Sevilla (IBiS)-CSIC, Spain; CIBERSAM, ISCIII, Spain.

[6]Mental Health Service, Virgen del Rocío University Hospital; Seville, Spain. Instituto de Biomedicina de Sevilla (IBiS) HUVR/CSIC/University of Seville / CIBERSAM, ISCIII; Seville, Spain.

[7]Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA.

[8]Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, PA, USA

[9]Department of Psychiatry. Marqués de Valdecilla University Hospital, IDIVAL, School of Medicine, University of Cantabria; Santander, Spain.

[10]Department of Psychiatry, University of Cambridge; Cambridge, UK.

[11]Instituto de Biomedicina de Sevilla (IBiS) HUVR/CSIC/University of Seville / CIBERSAM, ISCIII;

Seville, Spain.

Correspondence to: Rafael Romero García

Full address: Avda. Doctor Fedriani S/N, 41009, Seville (Spain)

Telephone: +34 954551768

E-mail: rr480@cam.ac.uk

Running title: Centiles and clinical outcomes in psychosis.

Keywords: Psychosis, normative modelling, centiles, cognition, longitudinal MRI, schizophrenia

ABSTRACT

Background: Clinical progression during psychosis has been closely associated with grey

matter abnormalities resulting from atypical brain development. However, the complex

interplay between psychopathology and heterogeneous maturational trajectories challenges

the identification of neuroanatomical features that anticipate symptomatic decline.

Aims: To investigate cortical volume longitudinal deviations in FEP using normative modelling,

exploring their relationship with long-term cognitive and symptomatic outcomes, as well as

their cytoarchitectural and neurobiological underpinnings.

Methods: We collected MRI, cognitive, and symptomatic data from 195 healthy controls and

357 drug-naïve or minimally medicated FEP individuals that were followed up 1,3,5 and 10

years after the first episode (1209 MRI scans and assessments in total). Using normative

modelling, we derived subject-specific centile scores for cortical volume to investigate atypical

deviations in FEP and their relationship to long-term cognitive and symptomatic deterioration.

The resulting centile association maps were further characterized by examining their

cytoarchitectural and neurobiological attributes using normative atlases.

Results: FEP centiles showed a widespread reduction at treatment initiation, with longitudinal

analysis showing an increase during treatment time, indicating convergence toward normal

maturation trajectories. Interestingly, this effect was reduced in highly medicated individuals.

Additionally, we found that cognitive impairments experienced during early FEP stages

worsened under long-term medication. Positive symptomatology was negatively associated

with regional centiles, and individuals with higher centiles benefited most from treatment.

Cytoarchitectural and neurobiological analyses revealed that regional centiles related to FEP,

as well as to symptomatology, were associated with specific molecular features, such as

regional serotonin and dopamine receptor densities.

Conclusions: Collectively, these findings underscore the potential use of centile-based

normative modelling for a better understanding of how atypical cortical development

contributes to the long-term clinical progression of neurodevelopmental conditions.

INTRODUCTION

Atypical brain structure in FEP

First Episode Psychosis (FEP) is characterised by heterogeneous clinical presentations [1],

temporal progression [2], and responses to medication [3]. Cross-sectional MRI studies

consistently report alterations in frontal and temporal cortices [4], with some identifying

changes in insular [5], parietal [6], and occipital regions [7]. Longitudinal studies have additionally

revealed progressive cortical deterioration in FEP, especially in frontal and temporal regions,

over 1 [8], 2–3 [9], 5 [10], and 10 years [11]. Despite these findings, the complex interplay between

brain development, sex, and neurodevelopmental pathophysiology complicates the

disentanglement of their individual contributions to brain structure and function. Normative

modelling addresses this by creating "growth charts" of brain development [12], allowing

individuals to be ranked and assigned centile scores based on deviations from expected

neurotypical trajectories. This approach has been used to identify abnormal structural

subtypes in autism [13] and deviations in ADHD symptoms [14]. In psychosis, normative modelling

reveals deviations in cortical thickness in temporal areas during high-risk states [15] and across

the cortex in FEP [16], with these deviations diminishing during treatment [17].

Brain structure and clinical outcomes

MRI studies have also extensively explored the clinical presentation of FEP, linking positive

symptoms, such as hallucinations and delusions, to thinning in frontal [18] and temporal [19]

cortices. Conversely, negative symptoms, like anhedonia and social withdrawal, are associated

with reduced orbitofrontal thickness [20]. The effects of antipsychotics on brain structure remain

debated, with studies reporting both grey matter reductions [21] and increased regional

thickness [22]. Cognitive decline in FEP has been observed prior to the onset of psychosis [23],

while post-onset trajectories vary, with reports of stabilization [24], decline [25], or improvement

[26]. Normative modelling has shown neurocognitive delays in youth reporting psychotic

symptoms [27], but the long-term impact of antipsychotics on cognition remains uncertain [28].

Regional vulnerability to atypical development

The spatial patterns of cortical deterioration shared across psychiatric and neurological conditions have been interpreted as a reflection of differential regional vulnerability to pathology [29]. Under this hypothesis, cortical vulnerability to psychosis-related deterioration may reflect regional differences in cellular composition, neurotransmitter receptors, and metabolism [29], with regions of high serotonin and acetylcholine receptor density showing greater atypical deviations [30]. In this study, we hypothesize that FEP patients exhibit atypical brain development influenced by treatment and medication, which impacts cognitive and symptom progression. We analysed baseline and 10-year follow-up longitudinal data to explore associations between brain deviations, clinical diagnosis, medication, cognition, and symptoms. Using cytoarchitectonic and neurobiological atlases, we additionally characterized psychosis-related brain deviations based on neurotransmitters, cell types, microstructure, and metabolism.

METODOLOGY

Subjects

MRI and phenotypic data were collected from healthy controls (n = 195; 120 males; mean age = 29.1 ± 7.63 years) and individuals with first-episode psychosis (FEP; n = 357; 213 males; mean age = 29.8 ± 8.76 years), who were followed longitudinally. Follow-up assessments were conducted at baseline (193 controls, 333 FEP), 1 (62 controls, 96 FEP), 3 (51 controls, 136 FEP), 5 (76 controls, 70 FEP), and 10 (91 controls, 101 FEP) years (See Fig. S1 and S2 for flow diagram for study participants and alluvial diagram of attrition).

Recruitment was conducted through the Program for Attention to the Initial Phases of Psychoses (PAFIP) at Marqués de Valdecilla University Hospital and Valdecilla Health Research Institute (IDIVAL) in Spain. The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2013. All procedures involving human subjects were approved by the CEIC-Cantabria (clinical trial numbers NCT0235832 and NCT02534363) and the Ethic committee of the University of Seville (2024-2534). Following a comprehensive explanation of the study, each participant provided written informed consent prior to enrolment. Participants in the clinical group met DSM-IV criteria for schizophrenia spectrum disorders, including schizophrenia (n=156), schizophreniform disorder (n=99), schizoaffective disorder (n=6), brief psychotic disorder (n=48), and psychosis not otherwise specified (n=24). See a full list of inclusion and exclusion

122 criteria in Supplementary Methods. Detailed demographic and clinical information stratified by
123 sex and diagnosis are provided in Supplemental Material (Figs. S3-S4 and Tables S1-S4).

Cognitive and symptom assessment

Cognition was assessed for the following domains: (1) verbal memory: Rey Auditory Verbal
Learning Test (RAVLT) long-term recall score; (2) visual memory: Rey Complex Figure test
(RCFT) long-term recall score; (3) motor dexterity: grooved pegboard (GP), time to complete
with dominant hand; (4) executive functions: Trail Making Test part B (TMTb); (5) working
memory: WAIS III-Backward Digits (BD) total score; (6) speed of processing: WAIS III-Digit
Symbol (DS) standard total score; (7) attention: Continuous Performance Test Degraded-
Stimulus (CPT-DS), the total number of correct responses [31]. For each cognitive test, z-scores
were computed by subtracting the mean and dividing by the standard deviation of the control
group's scores. Overall cognitive functioning was calculated as the mean z-score across the
seven cognitive tests for each individual. FEP participants were also assessed using the Scale
for the Assessment of Negative Symptoms (SANS, 21 items), Scale for the Assessment of
Positive Symptoms (SAPS, 30 items), and Brief Psychiatric Rating Scale (BPRS, 24 items).

Principal Component Analysis (PCA) was conducted on cognition and symptom items to
compare with average scores used in the calculations. Sensitivity analyses examined (i) the
impact of cannabis use and (ii) study dropout on cognitive and symptom measures.
Psychological evaluations were performed by experienced psychiatrists using the structured
clinical interview for DSM-IV, with diagnoses confirmed at 6 months.

MRI acquisition and volume extraction

Structural MRI scans were acquired using a 1.5T General Electric SIGMA System (GE,
Milwaukee, USA) and a 3T Philips Medical Systems MRI scanner (Achieva, Best, The
Netherlands) equipped with an 8-channel head coil. Baseline and follow-up scans for each
individual were consistently conducted using the same machine. The imaging protocol
included a T1-weighted image that underwent visual inspection for QC. The parameters for
1.5T were: TE=5ms, TR=24ms, NEX=2, rotation angle=45°, FOV=26×19.5cm, slice
thickness=1.5mm, voxel size=1.02x1.02x1.5 mm, and a matrix of 256×192, whereas for 3T
were TE = 3.7ms, TR=8.2ms, flip angle=8°, acquisition matrix=256×256, voxel size=0.94x0.94x1
mm and 160 contiguous slices. The longitudinal pipeline of FreeSurfer 7.0.0 (recon-all) was
used to estimate global cortical volume and regional volume of each region defined in the

Desikan–Killiany atlas (34 regions per hemisphere). One regional outlier (>5 SD from the mean)

was excluded. Raw regional volumetric data from both scanners were harmonised using

ComBatLS preserving age, sex and diagnosis variance [32].

Regional volumetric centile estimation

We leveraged the cross-sectional normative trajectories established by the BrainChart study,

which benchmarked cortical volumes from the Desikan-Killiany atlas against data from over

100,000 neurotypical individuals [12]. Based on these trajectories, we computed out-of-sample

centile estimates for our longitudinal sample, using the control cohort to account for scanner-

related offsets (https://github.com/brainchart/Lifespan). Following the Bethlehem et al. 2022

pipeline, the volumetric values of left and right homologous regions were averaged to obtain a

single measure per region, and centiles were subsequently computed from these averaged

values. Age-normed, sex-stratified, and site-corrected deviations were derived and expressed

as centile scores. Centile scores represent the relative position of an individual's grey matter

volume with respect to normative lifespan trajectories. Scores below 0.5 indicate volumes

lower than the median for age- and sex-matched individuals, whereas scores above 0.5

indicate volumes higher than the median. Residual effects of site or motion (Euler index) on

centile scores were assessed using ANOVA.

Baseline analyses using multiple regression

171   To evaluate the impact of FEP diagnosis on baseline centiles, a multiple regression was

172   performed for each cortical region using the following model:

$$regional\ centile \sim 1 + diagnosis + sex + age\ of\ inclusion + etiv\ (1)$$

173   where diagnosis was a binary variable (control vs. FEP), age of inclusion referred to

174   participants' age at the first scan, and etiv represented cranial volume residuals after age and

175   sex correction (which allowed us to account for anthropometric factors using a single variable).

176   Age of inclusion and etiv were Z-scored prior to regression. All p-values were corrected for

177   multiple comparisons across regions using false discovery rate (FDR).

Longitudinal analyses using Mixed Modelling

179   The longitudinal effects of disease and medication on centiles and clinical outcomes were

180   analysed using Mixed Modelling over 1,209 assessments (195 controls, 357 FEP). Antipsychotic

181   medication exposure was assessed at each visit (Fig. S5) and converted into chlorpromazine

182   equivalents (CPZ-equivalents) [33].

Linear Mixed Modelling for predicting regional centiles as a function of disease progression and treatment

Linear Mixed Modelling (LMM) was used to assess the impact of time from the first scan (for controls) and time from treatment initiation (for FEP), collectively referred to as time, in regional centiles. The contribution of age was separated between age of inclusion and time to be able to capture specific interaction effects between treatment time, medication and centiles trajectory in patients:

$$regional\ centile \sim 1 +\ diagnosis + sex\ +\ age\ of\ inclusion\ + etiv + medication \\ + time +\ time\ x\ diagnosis\ + medication\ x\ time + (1|\ subject)\ (2)$$

where, in addition to the aforementioned variables, we also considered: medication at the time of MRI acquisition (antipsychotic dose in CPZ-equivalents), time x diagnosis (interaction between time and diagnosis) and medication x time (interaction indicating whether medication alters the effect of treatment time on centiles) and "1|subject" as a random intercept to account for random subject-specific offsets overall. Age of inclusion, etiv, medication and time were Z-scored prior to regression.

Sensitivity analyses repeated these models using raw regional volumes instead of centiles as the dependent variable.

LMM for predicting cognitive functioning as a function of treatment and regional centiles

After exploring the effects of disease and treatment on centiles, we evaluated how these factors relate to overall cognitive functioning:

$$cognition \sim 1 +\ diagnosis +\ sex\ +\ age\ of\ inclusion\ +\ etiv\ +\ medication + time \\ + centile +\ time\ x\ diagnosis\ +\ medication\ x\ time \\ + centile\ x\ diagnosis\ + centile\ x\ time + (1|\ subject)\ \ (3)$$

Models were fitted independently for each region, resulting in one parameter estimate per region and covariate. For visualization, a cortical map was generated for each covariate to summarize the regional patterns of association. All p-values were corrected for multiple comparisons across regions using FDR.

Generalized Mixed Modelling for predicting clinical symptomatology as a function of treatment and regional centiles

Symptomatology (BPRS, SAPS, and SANS scores) was modelled as:

$$symptoms \sim 1 + \ sex \ + age \ of \ inclusion \ + \ etiv + centile + time + \ medication$$
$$+ \ medication \ x \ time + centile \ x \ medication + centile \ x \ time$$
$$+ \ (1| \ subject) \ (4)$$

Generalized Mixed Models with a Poisson distribution were used due to the count-like nature

of symptom scores and their alignment with exponential decay patterns. Separate analyses

were conducted for each region and for each psychometric scale.

Furthermore, for each scale, we conducted a mediation analysis to determine whether the

association between medication and symptoms was mediated by the regional centile most

strongly associated with symptoms. A bootstrap with 10,000 resamples was used to test for

the presence of average direct effect (ADE), average causal mediation effect (ACME) and the

total effect (ADE+ACME).

Cytoarchitectural characterization of centile associations

218 Cortical centiles associated with phenotypic variables (diagnosis, medication, BPRS, SAPS,

219 SANS) were mapped onto the cortical hierarchies defined by Mesulam atlas (unimodal,

220 paralimbic, idiotypic, heteromodal, https://github.com/ucam-department-of-

221 psychiatry/maps_and_parcs, Table S5, [34]. ANOVA tests and Tukey post-hoc analyses were used

222 to identify differential distributions of centile associations across Mesulam areas.

Neurobiological mapping of centile associations

Centile-phenotypic associations were also profiled using 46 molecular and microarchitectural

maps derived from MRI/PET studies, expanding on the methodology presented on [35] and

implemented at https://github.com/netneurolab/neuromaps and

https://github.com/RafaelRomeroGarcia/NeurobiologyCentilesPsychosis. These maps

included: neurotransmitter receptors ($5-HT_{1A}$, $5-HT_{1B}$, $5-HT_{2A}$, $5-HT_4$, $5-HTT$, H_3, D_1, D_2, DAT,

NET, $\alpha_4\beta_2$, VAChT, CB_1, M_1, MOR, $mGluR_5$, NMDA, GABA), cell types (astrocytes, endothelial

cells, microglia, oligodendrocytes, oligodendrocytes precursors, excitatory neurons, inhibitory

neurons), cortical layers (I-VI), microstructural properties (synapse density, neurotransmitter

PC1, gene expression PC1 [which is highly driven by cell types [36]], cortical thickness, myelin),

metabolism (glycolytic index, cerebral blood flow, cerebral blood volume, oxygen metabolism

and glucose metabolism), cortical expansion (evolutionary expansion, developmental

expansion, allometric scaling from Philadelphia Neurodevelopmental Cohort, allometric scaling

from National Institutes of Health). See Table S6 for the full list of neurobiological features

included in the analysis.

Principal Component – Canonical Correlation Analysis (PC-CCA;

https://github.com/RafaelRomeroGarcia/cca_pls_toolkit) was used to identify combinations of

neurobiological features that best explained centile-phenotypic associations [37]. PC-CCA

reduces data dimensionality using PCA to minimize overfitting and then identifies the linear

combination (weighted sum of loadings) of the neurobiological maps that best predicts the

inter-regional variance of each centiles-phenotypic association map. Statistical significance was

evaluated using spatial autocorrelation-preserving permutation tests (spin tests;

https://github.com/frantisekvasa/rotate_parcellation) with 10,000 parcellation-specific

rotations. To validate the multiple regression patterns identified with PC-CCA, we conducted a

sensitivity analysis with Partial Least Squares (PLS). PLS maximizes the covariance between the

two variable sets, providing a robust alternative when collinearity might affect the canonical

solution [37].

RESULTS

Impact of diagnosis and treatment on centiles

Using multiple regression on baseline data, FEP patients demonstrated significantly lower total

grey matter volume centiles compared to controls (T = -6.20, p < 10^{-8}), but no reductions in

total white matter centiles (T = 1.67, P = 0.095, Table S7; Table S8 for model fit estimates).

Consistently, regional analyses showed widespread cortical reductions in centiles associated

with diagnosis (**Fig. 1**, Baseline). Covariates such as age of inclusion and etiv correlated

positively with centiles, while females exhibited lower centiles (**Fig. 1**, Baseline). Effect sizes

and FDR-corrected significance levels are fully provided in the supplementary data. Centiles

were not significantly associated with motion artifacts quantified using the Euler index

(Spearman's rho = -0.016, P = 0.587; Fig. S6). As a sensitivity analysis, we recalculated the

model including an age of inclusion x diagnosis interaction term, which revealed that the

positive effect of age of inclusion on centiles was significantly attenuated in patients (T = −

2.73, P = 0.006).

Longitudinal analyses using LMM over 10 years revealed that longer treatment duration in FEP

patients was associated with increased global centile scores, progressively approaching

normative values (T = 4.02, p < 10^{-4}; Table S9). Regionally, significant diagnosis-centile

associations were observed across the whole cortex (**Fig. 1**, longitudinal). The main effect of

time showed both positive and negative correlations with centiles; however, the time × FEP

interaction revealed a generalized positive association (see Fig. S7A for an illustration of this

interaction). Medication (CPZ-equivalent) was negatively associated with centiles, showing also

a negative interaction with time. Despite the robust effect of medication, substantial inter-

subject variability in centiles persisted between individuals with low versus high medication

doses (Fig. S8).

These LMM analyses were repeated using raw volumes instead of centiles. As illustrated in Fig.

S9, the principal age- and time-related negative association captured the expected decline in

regional volume with aging. Consistent with the centile results, this model also indicated a

positive time x FEP interaction, which was attenuated by medication.

Fig. 1. Associations between phenotypic data and covariates with regional centiles. **Top panel.**

Contribution of each variable to the multiple regression of baseline data. **Bottom panel**

Contribution of each variable to the LMM of longitudinal changes in centiles (up to 10 years

follow-up). Scale represents t-values associated with each regression parameter. Non-

significant contributions ($P_{fdr} \geq 0.05$) are depicted with desaturated colours.

Regional centiles associated with cognitive impairment

Principal component analysis (PCA) of cognitive subscales revealed a first PC explaining 45.3%

of the variance, with similar weights across the seven subscales (Table S10), so for simplicity,

the mean score was used in subsequent analyses. Cognitive function was negatively associated

with FEP diagnosis (**Fig. 2**, diagnosis) but did not correlate with regional centiles (**Fig. 2**, centile

- psychosis interaction). Accordingly, the high individual variability limits reliable subgrouping

based on centile trajectories (Fig. S10). The observed positive effect of medication, together

with the negative medication x time interaction, indicates that the initial therapeutic benefits

are attenuated with prolonged treatment (illustrated in Fig. S7B). As a sensitivity analysis,

models were repeated by categorizing individuals as low-medicated (CPZ ≤ 300) or highly

medicated (CPZ > 300). Interestingly, the global grey matter volume centile showed a weak but

significant association with cognitive performance in patients (P=0.04, Table S11). Time had a

negative impact on cognition among highly medicated individuals (β_{time}- $\beta_{time\ x\ high\text{-}medication}$ =0.13

- 0.21 = –0.08; Table S11).

Fig. 2. Associations between phenotypic data, covariates and centiles with cognitive performance. Contribution of each variable to the LMM of longitudinal changes in cognition (up to 10 years follow-up). Scale represents t-values associated with each regression parameter. Non-significant contributions ($P_{fdr} \geq 0.05$) are depicted with desaturated.

Regional centiles associated with symptomatology

Treatment time correlated negatively with BPRS, SAPS, and SANS scores, indicating symptom reduction over time (**Fig. 3**; see Table S8 for model fit estimates). Medication was associated with reductions in BPRS and SAPS scores but increased SANS scores, likely due to pharmacological specificity for positive symptoms. A positive medication x time interaction

indicates that symptom improvement with time was less pronounced in highly medicated
patients. Positive symptoms (SAPS) were negatively associated with centiles, particularly
overlapping with BPRS, whereas SANS showed a weak correlation with centiles. Younger age at
onset was linked to more severe positive symptoms (SAPS). The sensitivity analysis comparing
low- versus highly medicated patients revealed that, although attenuated, the effect of time
on symptoms remained positive in the highly medicated group (Table S11). No significant
differences were observed in cognitive or symptom scores between cannabis users and non-
users (Table S12) or between participants who completed the study and those who dropped
out (Table S13).

Additionally, mediation analyses were performed to examine the potential mediating effects
of centiles and time on the association between medication and symptom severity. No
evidence of centile mediation was observed at treatment initiation; however, significant long-
term mediation effects were identified. Specifically, the association between medication and
symptoms was fully mediated by the insula for SAPS ($\beta=0.15$, CI:[0.04,0.27]) and partially
mediated by the pars orbitalis cortex for SANS ($\beta=-0.05$, CI:[-0.11,-0.01], Fig. S11).

Fig. 3. Associations between phenotypic data, covariates and centiles with symptomatology.
Contribution of each variable to the GMM of longitudinal changes in BPRS, SAPS and SANS

(each column represents different models). Scale represents the Wald z-statistic associated
with each regression parameter. Non-significant contributions ($P_{fdr} \geq 0.05$) are depicted with
desaturated colours.

Cytoarchitectural and neurobiological characterization of FEP-related regional centiles

Using the Mesulam cytoarchitectonic atlas [34], we characterized regional associations between
centiles, cognition, and symptoms. Centiles linked to BPRS or SANS did not show a preferential
topographic Mesulam distribution. However, SAPS displayed significantly stronger negative
associations in paralimbic regions compared with idiotypic areas (ANOVA, Post-hoc Tukey, P_{fdr}
<0.05, **Fig. 4A**). PCA-CCA was used to capture associations between neurobiological data from
normative individuals [35] and centiles related to clinical outcomes. Neurobiological mapping
revealed that regions associated with FEP diagnosis (Fig. 1) co-located with areas rich in
neurotransmitters such as $5-HT_{1B}$, $5-HT_{2A}$, $5-HT_6$, as well as neurons and metabolic features
(P=0.004, **Fig. 4B**, negative loadings). Conversely, FEP diagnosis-related regions were
associated with lower glial cell densities and $5-HT_{1A}$ neurotransmitter levels (positive loadings).
Neurobiological mapping for regions negatively impacted by medication was not significant.

Neurobiological features were significantly co-located with the centile-symptoms associations
(**Fig. 4C**). Specifically, centiles associated with BPRS co-located with serotonin $5-HT_{1A}$, D_2, and
norepinephrine transporters, as well as with glial cells (P=0.009). Regions showing negative
correlations between centiles and BPRS (i.e. associated with symptom improvement) were co-
located with $5-HT_{1B}$, GABA, NMDA receptors, inhibitory neurons, myelin, developmental
expansion and allometric scaling. Centiles associated with SAPS recovery were co-located with
$5-HT_{1A}$, $5-HT_4$, cannabinoid receptors, D_2, norepinephrine transporters, glia and cortical
thickness (P=0.012). Centiles correlated with SANS were co-located with $5-HT_4$, cortical
thickness and metabolism (P= 0.01).

Collectively, these results reveal a significant co-location of atypical brain maturation in FEP
with specific neurobiological factors, suggesting that they may play an important role in
shaping the structural vulnerability to FEP symptomatology. Consistency analyses using PLS
instead of PCA-CCA yielded highly similar neurobiological loading estimates (all r-values > 0.78;
Fig. S12).

Fig. 4. Cytoarchitectural and neurobiological characterisation of FEP-related centiles. **A)** Distribution of t-values shown in Fig. 3 across the four cortices delineated in the atlas of Mesulam. Each dot represents a brain region in the Desikan-Killiany atlas. **B)** Neurobiological maps co-located with the diagnosis-centile and medication-centile associations. Positive loadings indicate neurobiological features that are co-located with regions where centiles were positively associated with the variables of interest (in this case, diagnosis and medication). Conversely, negative loadings indicate co-location with regions negatively associated with the variable of interest. **C)** Neurobiological maps co-located with the association between centiles

366 and clinical outcomes (BPRS SAPS, and SANS). "N.S." denotes non-significant models

367 ($P_{fdr} \geq 0.05$). For significant models, only significant ($P_{fdr} < 0.05$) loadings are displayed.

DISCUSSION

In this study, we examined cortical volume deviations using normative centiles models in both

neurotypical and FEP participants scanned over the course of 10 years. Our findings indicated

that FEP participants had lower regional centiles than controls in multiple cortical areas, a

difference that decreased in intensity over the treatment period. However, this convergence

between patients and controls was less pronounced in those who were highly medicated.

Psychotic symptomatology was negatively correlated with centiles co-located with regions

with high serotonin receptor densities. These results highlight the value of normative

approaches for better understanding the long-term relationship between cortical maturation

and clinical profiles in psychosis.

Our normative analysis revealed atypical developmental values in FEP patients who exhibited a

generalised reduction in regional centile scores [16]. Previous studies have extensively reported

reductions in cortical volume and thickness at different stages of psychosis-related conditions

[5,7,16]. As shown by the ENIGMA consortium, although frontal and temporal cortices are the

regions showing the strongest effect sizes when compared to normative controls,

schizophrenia is also characterised by a generalised reduction over the whole cortex [38].

Nevertheless, a major challenge in traditional case-control studies is the lack of personalised

metrics capable of detecting individuals with atypical neurodevelopment. Conversely,

normative modelling leverages data from thousands of individuals for identifying participants

with abnormal trajectories. Using this approach, Worker et al. 2023 [16], demonstrated that a

large and widespread number of extreme negative deviations in cortical thickness centiles

among FEP exist, revealing that this condition is characterised not only by a diminished group-

average cortical thickness but also by specific individuals that exhibit severe thickness

reductions.

The combination of normative modelling with long-term longitudinal MRI revealed that

centiles increased during the treatment period of FEP participants. These findings indicate that

grey matter reductions are more pronounced during the early stages of psychosis [39], whereas

the age-related volume decreases observed in controls are less pronounced in late psychosis

[22]. Berthet et al. (2025) [17] also reported this trend toward a reduced difference over time

between controls and FEP patients when investigating cortical thickness using normative

modelling. Since this study did not include untreated patients, we cannot disentangle the

specific effects of treatment from the natural course of the disease and potential late effects
of neurodegenerative pathogenesis [40]. Medication has been previously associated with grey
matter loss [41], specifically attributed to caspase-3-mediated neurotoxicity [42]. In this line, we
also found that high medication doses were associated with generalized cortical reduction. As
suggested by Fusar-Poli et al. 2013 metanalysis [43], long-term GM reductions may be the
consequence of the cumulative exposure to the antipsychotics, a finding also supported by
other studies [21].

While describing the anatomical alterations related to the progression and treatment of
psychosis is of great interest, understanding how these changes impact patients' cognitive
functionality is of crucial clinical importance. We reported reduced cognitive abilities in drug-
naïve and minimally medicated FEP participants immediately after the onset, suggesting that
impairment occurs even before the first episode [23]. Cognitive functionality also improved
throughout the treatment, indicating that while medication targets positive symptoms, it may
also lead to cognitive improvement, albeit as an indirect effect. [23]. Previous studies have also
demonstrated cognitive improvement in patients after one [44] or three [45] years of antipsychotic
treatment. Nevertheless, our LMM additionally found that medication influenced the
association between treatment duration and cognitive function, leading to an attenuation of
cognitive recovery over time for patients with higher medication doses. In line with this
observation, Kawai et al. 2006 [46] demonstrated that dose-reductions lead to improvements in
cognitive performance in a limited sample of individuals treated with multiple conventional
antipsychotics.

Unsurprisingly, treatment yielded a positive effect on FEP-related symptomatology. As
expected, both time and medication primarily had an impact on positive symptoms.
Conversely, time had a positive but weaker effect on the reduction of negative symptoms.
Despite the fact that medication, especially first-generation antipsychotics, does not alleviate
negative symptoms, meta-analyses of placebo-control trials have indeed revealed that most
treatments can help reduce negative symptomatology [47]. Nevertheless, here, we observed
opposite trends in the model slopes of time (negative) and medication (positive) with SANS,
indicating that heavily medicated individuals do not experience negative symptoms
improvements over time. This may reflect the diverse and distinct recovery trajectories of
illness, with a significant proportion of patients experiencing relapse and showing no
improvement in negative symptoms [48]. FEP symptomatology was also associated with regional
volumes, with higher centiles values being associated with lower positive symptoms. Similarly,
previous studies have associated positive symptoms with cortical alterations in prefrontal,

temporal and parietal areas [19]. Conversely, negative symptoms exhibited a weak correlation

with centiles, suggesting that while treatment and medication may provide moderate

improvement in this domain, these symptoms remain relatively stable and do not significantly

influence cortical plasticity. However, further placebo-controlled trials will be necessary to

elucidate this [48].

Neurobiologically, serotonin neurotransmitters were predominantly present in regions

associated with psychosis diagnosis. This may be related with the role of this neurotransmitter

mediating the effect of antipsychotic medication which affects mood and cognitive function [49].

We also reported differences in centile associations across receptor subtypes such as $5HT_{1A}$

and $5HT_{2A}$ which could be a reflection of its complex role in psychosis [50]. Additionally, the co-

location of dopamine receptors in regions associated with symptoms suggests a potential

pathway whereby elevated levels of antipsychotic medications disproportionately affect

dopaminergic regions. Moreover, diagnosis and symptom-related centiles were not only

associated with neuronal density maps but also with glial cells, indicating a potential

involvement of immunological and inflammatory risk factors [51].

Limitations

Several limitations must be acknowledged. Firstly, the primary inclusion criterion was the

diagnosis of FEP at baseline, regardless of subsequent follow-up diagnoses, which

predominantly included schizophrenia but also other psychotic disorders. Secondly, the use of

CPZ-equivalents provides a simplified representation of the heterogeneous antipsychotic

treatments across the sample, allowing us to capture the overall medication effect with a

single parameter. However, different classes of antipsychotics may have differential effects on

centiles and clinical outcomes. Including all drug-specific doses was not feasible, as this would

substantially increase the number of variables and the risk of overfitting. Finally, higher

medication doses were generally prescribed to individuals with more resistant positive

symptoms. However, these prescriptions were influenced by factors such as age of onset and

treatment duration, complicating the disentanglement of individual contributions in the

models.

This brain-wide association study (BWAS) demonstrates that centiles are associated with

clinical outcomes in FEP. Nevertheless, growing evidence highlights important concerns: BWAS

are susceptible to inflated effect sizes and low replication rates unless samples include

thousands of individuals [52]. Recent findings by Kang et al. 2024, have shown, however, that

longitudinal designs can substantially improve replicability [53]. In this study, participants were

comprehensively assessed over a 10-year period. While replication gains plateau after the first

follow-up, particularly for structural markers, which exhibit limited within-subject variability,

longitudinal assessments remain valuable for capturing the pronounced phenotypic decline in

cognition and symptoms over time in FEP. Importantly, this high within-subject phenotypic

variability is critical for enhancing replicability, especially when modelled separately from

between-subject variability [53], as implemented here.

We aimed to maintain the models as parsimonious as possible. With 552 participants, up to 11

fixed variables and at least 449 degrees of freedom, the resulting balance was appropriate for

robust and replicable estimation of model parameters [54]. Nevertheless, aspects such as the

inclusion of moderate covariates, potential underlying collinearity, or missing data further

contribute to the complexity of assessing the actual statistical power and the potential risk of

overfitting of the models.

Centiles derived from cross-sectional brain charts have demonstrated to underestimate

longitudinal brain changes, resulting in inaccurate predictors of longitudinal individual changes

[55]. In this study, which includes extensive follow-up data, our objective was not to perform

individualised age-related predictions, but to identify volumetric deviations associated with

long-term cognitive and symptomatic outcomes in FEP. To account for residual age effects

retained by the centiles, both age of inclusion and time were included as main effects in the

models. However, longitudinal normative modelling was not performed due to the limited

sample size. Future work will benefit from calibrating brain reference charts with longitudinal

datasets [55]. This will be crucial for characterizing individual-level trajectories and for identifying

subgroups that may account for clinical heterogeneity and differences in treatment response.

Conclusions

This study applied a normative modelling approach to demonstrate that FEP is characterised

by regional decreases in cortical centiles. Centiles recovered to normative values during

treatment but they were negatively affected by high doses of long-term medication. Similarly,

improvements in cognitive abilities and symptomatology were positively associated with time,

although were negatively influenced by prolonged medication use. Regions sensitive to

symptomatology co-located with higher serotonin receptor densities and other neurobiological

features. Collectively, these findings provide critical insights into the long-term interactions

between cortical structure, treatment, medication, cognitive function, and symptom profiles.

Data and Code availability

Acknowledgements

503 We thank Agoston Mihalik, Golia Shafiei, Bratislav Misic, Victor Ortiz and Lifespan Brain Chart
504 Consortium for their contribution.

Funding

RRG is funded by the EMERGIA Junta de Andalucía program (EMERGIA20_00139), ERANET
Neuron JTC 2023 (ERP-2023-23684211), and the Plan de Consolidación (CNS2023-143647).
Both RRG and CAM, are funded by the *Plan de Generación de Conocimiento* from the Agencia
Estatal de Investigación (PID2021-122853OA-I00). JS is funded by the Psychosis Immune
Mechanism Stratified Medicine Study (PIMS), UK Medical Research Council, MR/S037675/1. All
research at the Department of Psychiatry in the University of Cambridge is supported by the
NIHR Cambridge Biomedical Research Centre (NIHR203312) and the NIHR Applied Research
Collaboration East of England. The views expressed are those of the author(s) and not
necessarily those of the NIHR or the Department of Health and Social Care

Author Contributions

C.A-M performed data curation, methodological design, data analysis, and drafted the
manuscript; N.G-S-M, R.A.I.B, L.D, M.A-N, P.S, A.P, M.M-C, M.C R, J.S, R.A-A, J.V-B, J.S, M.R-V,
B.C-F and R.R-G contributed to data acquisition, provided advice on data analysis, and
participated in writing and editing the manuscript. R.R.G. also contributed to
conceptualization, first manuscript draft, and supervision of the work. All authors approved
the submitted version of the manuscript.

Competing interests

523 RAIB and JS hold equity in and are directors of Centile Bioscience. All other authors declare
524 that they have no known competing interests.

REFERENCES

1 Voineskos AN, Jacobs GR, Ameis SH. Neuroimaging Heterogeneity in Psychosis:
Neurobiological Underpinnings and Opportunities for Prognostic and Therapeutic
Innovation. *Biological Psychiatry* 2020; **88**: 95–102.

2   Prakash J, Chatterjee K, Srivastava K, Chauhan VS. First-episode psychosis: How long does
it last? A review of evolution and trajectory. *Ind Psychiatry J* 2021; **30**: 198–206.

3   Leucht S, Crippa A, Siafis S, Patel MX, Orsini N, Davis JM. Dose-Response Meta-Analysis of
Antipsychotic Drugs for Acute Schizophrenia. *AJP* 2020; **177**: 342–53.

4   Oertel-Knöchel V, Knöchel C, Rotarska-Jagiela A, Reinke B, Prvulovic D, Haenschel C, *et al.*
Association between Psychotic Symptoms and Cortical Thickness Reduction across the
Schizophrenia Spectrum. *Cerebral Cortex* 2013; **23**: 61–70.

5   Crespo-Facorro B. Insular cortex abnormalities in schizophrenia: a structural magnetic
resonance imaging study of first-episode patients. *Schizophrenia Research* 2000; **46**: 35–
43.

6   Yildiz M, Borgwardt SJ, Berger GE. Parietal Lobes in Schizophrenia: Do They Matter?
Schizophr Res Treatment 2011; **2011**: 581686.

7   Tordesillas-Gutierrez D, Ayesa-Arriola R, Delgado-Alvarado M, Robinson JL, Lopez-Morinigo
J, Pujol J, *et al.* The right occipital lobe and poor insight in first-episode psychosis. *PLoS One*
2018; **13**: e0197715.

8   Del Re EC, Stone WS, Bouix S, Seitz J, Zeng V, Guliano A, *et al.* Baseline Cortical Thickness
Reductions in Clinical High Risk for Psychosis: Brain Regions Associated with Conversion to
Psychosis Versus Non-Conversion as Assessed at One-Year Follow-Up in the Shanghai-At-
Risk-for-Psychosis (SHARP) Study. *Schizophr Bull* 2021; **47**: 562–74.

9   Cobia DJ, Smith MJ, Wang L, Csernansky JG. Longitudinal progression of frontal and
temporal lobe changes in schizophrenia. *Schizophrenia Research* 2012; **139**: 1–6.

10   van Haren NEM, Hulshoff Pol HE, Schnack HG, Cahn W, Mandl RCW, Collins DL, *et al.* Focal
gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up
study. *Neuropsychopharmacology* 2007; **32**: 2057–66.

11   Rodriguez-Perez N, Ayesa-Arriola R, Ortiz-García de la Foz V, Setien-Suero E, Tordesillas-
Gutierrez D, Crespo-Facorro B. Long term cortical thickness changes after a first episode of
non- affective psychosis: The 10 year follow-up of the PAFIP cohort. *Progress in Neuro-*
Psychopharmacology and Biological Psychiatry 2021; **108**: 110180.

12   Bethlehem RAI, Seidlitz J, White SR, Vogel JW, Anderson KM, Adamson C, *et al.* Brain
charts for the human lifespan. *Nature* 2022; **604**: 525–33.

13   Shan X, Uddin LQ, Xiao J, He C, Ling Z, Li L, *et al.* Mapping the Heterogeneous Brain
Structural Phenotype of Autism Spectrum Disorder Using the Normative Model. *Biological*
Psychiatry 2022; **91**: 967–76.

14   Marquand AF, Rezek I, Buitelaar J, Beckmann CF. Understanding Heterogeneity in Clinical
Cohorts Using Normative Models: Beyond Case-Control Studies. *Biological Psychiatry*
2016; **80**: 552–61.

15   ENIGMA Clinical High Risk for Psychosis Working Group. Normative Modeling of Brain
Morphometry in Clinical High Risk for Psychosis. *JAMA Psychiatry* 2024; **81**: 77–88.

16   Worker A, Berthert P, Lawrence AJ, Kia SM, Arango C, Dinga R, *et al.* Extreme deviations
from the normative model reveal cortical heterogeneity and associations with negative
symptom severity in first-episode psychosis from the OPTiMiSE and GAP studies. *Transl*
Psychiatry 2023; **13**: 1–9.

17   Berthet P, Haatveit BC, Kjelkenes R, Worker A, Kia SM, Wolfers T, *et al.* A 10-Year
Longitudinal Study of Brain Cortical Thickness in People with First-Episode Psychosis Using
Normative Models. *Schizophrenia Bulletin* 2024; **51**: 95–107.

18   Padmanabhan JL, Tandon N, Haller CS, Mathew IT, Eack SM, Clementz BA, *et al.*
Correlations Between Brain Structure and Symptom Dimensions of Psychosis in
Schizophrenia, Schizoaffective, and Psychotic Bipolar I Disorders. *Schizophrenia Bulletin*
2015; **41**: 154–62.

19   Walton E, Hibar DP, van Erp TG, Potkin SG, Roiz-Santiañez R, Crespo-Facorro B, *et al.*
Positive symptoms associate with cortical thinning in the superior temporal gyrus via the
ENIGMA-Schizophrenia consortium. *Acta Psychiatr Scand* 2017; **135**: 439–47.

20   Walton E, Hibar DP, van Erp TGM, Potkin SG, Roiz-Santiañez R, Crespo-Facorro B, *et al.*
Prefrontal cortical thinning links to negative symptoms in schizophrenia via the ENIGMA
consortium. *Psychol Med* 2018; **48**: 82–94.

21   Vita A, De Peri L, Deste G, Barlati S, Sacchetti E. The Effect of Antipsychotic Treatment on
Cortical Gray Matter Changes in Schizophrenia: Does the Class Matter? A Meta-analysis
and Meta-regression of Longitudinal Magnetic Resonance Imaging Studies. *Biol Psychiatry*
2015; **78**: 403–12.

22   Goghari VM, Smith GN, Honer WG, Kopala LC, Thornton AE, Su W, *et al.* Effects of eight
weeks of atypical antipsychotic treatment on middle frontal thickness in drug-naïve first-
episode psychosis patients. *Schizophrenia Research* 2013; **149**: 149–55.

23   Bora E, Murray RM. Meta-analysis of cognitive deficits in ultra-high risk to psychosis and
first-episode psychosis: do the cognitive deficits progress over, or after, the onset of
psychosis? *Schizophr Bull* 2014; **40**: 744–55.

24   McCleery A, Nuechterlein KH. Cognitive impairment in psychotic illness: prevalence, profile
of impairment, developmental course, and treatment considerations. *Dialogues Clin*
Neurosci 2019; **21**: 239–48.

25   Fett A-KJ, Velthorst E, Reichenberg A, Ruggero CJ, Callahan JL, Fochtmann LJ, *et al.* Long-
term Changes in Cognitive Functioning in Individuals With Psychotic Disorders: Findings
From the Suffolk County Mental Health Project. *JAMA Psychiatry* 2020; **77**: 387–96.

26   Burgher B, Scott J, Cocchi L, Breakspear M. Longitudinal changes in neural gain and its
relationship to cognitive control trajectory in young adults with early psychosis. *Transl*
Psychiatry 2023; **13**: 1–9.

27   Gur RC, Calkins ME, Satterthwaite TD, Ruparel K, Bilker WB, Moore TM, *et al.*
Neurocognitive Growth Charting in Psychosis Spectrum Youths. *JAMA Psychiatry* 2014; **71**:
366–74.

28 Husa AP, Moilanen J, Murray GK, Marttila R, Haapea M, Rannikko I, *et al.* Lifetime
antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a
general population birth cohort. *Psychiatry Res* 2017; **247**: 130–8.

29 Hettwer MD, Larivière S, Park BY, van den Heuvel OA, Schmaal L, Andreassen OA, *et al.*
Coordinated cortical thickness alterations across six neurodevelopmental and psychiatric
disorders. *Nat Commun* 2022; **13**: 6851.

30 García-San-Martín N, Bethlehem RA, Mihalik A, Seidlitz J, Sebenius I, Alemán-Morrillo C, *et*
al. Molecular and micro-architectural mapping of abnormal gray matter developmental
trajectories in psychosis. 2023; : 2023.12.11.23299652.

31 Rodríguez-Sánchez JM, Setién-Suero E, Suárez-Pinilla P, Son JMV, Vázquez-Bourgon J,
López PG, *et al.* Ten-year course of cognition in first-episode non-affective psychosis
patients: PAFIP cohort. *Psychological Medicine* 2022; **52**: 770–9.

32 Gardner M, Shinohara RT, Bethlehem RAI, Romero-Garcia R, Warrier V, Dorfschmidt L, *et*
al. ComBatLS: A location- and scale-preserving method for multi-site image harmonization.
bioRxiv 2024; : 2024.06.21.599875.

33 Danivas V, Venkatasubramanian G. Current perspectives on chlorpromazine equivalents:
Comparing apples and oranges! *Indian J Psychiatry* 2013; **55**: 207–8.

34 Mesulam M-M, Mesulam M-M, editors. *Principles of behavioral and cognitive neurology.*
(2. ed.) Oxford Univ. Press, 2000.

35 Hansen JY, Shafiei G, Markello RD, Smart K, Cox SML, Nørgaard M, *et al.* Mapping
neurotransmitter systems to the structural and functional organization of the human
neocortex. *Nat Neurosci* 2022; **25**: 1569–81.

36 Dear R, Wagstyl K, Seidlitz J, Markello RD, Arnatkevičiūtė A, Anderson KM, *et al.* Cortical
gene expression architecture links healthy neurodevelopment to the imaging,
transcriptomics and genetics of autism and schizophrenia. *Nat Neurosci* 2024; **27**: 1075–
86.

37 Mihalik A, Chapman J, Adams RA, Winter NR, Ferreira FS, Shawe-Taylor J, *et al.* Canonical
Correlation Analysis and Partial Least Squares for Identifying Brain-Behavior Associations:
A Tutorial and a Comparative Study. *Biol Psychiatry Cogn Neurosci Neuroimaging* 2022; **7**:
1055–67.

38 Thompson PM, Jahanshad N, Ching CRK, Salminen LE, Thomopoulos SI, Bright J, *et al.*
ENIGMA and global neuroscience: A decade of large-scale studies of the brain in health
and disease across more than 40 countries. *Transl Psychiatry* 2020; **10**: 100.

39 Pantelis C, Yücel M, Wood SJ, Velakoulis D, Sun D, Berger G, *et al.* Structural brain imaging
evidence for multiple pathological processes at different stages of brain development in
schizophrenia. *Schizophr Bull* 2005; **31**: 672–96.

40 Woods BT. Is Schizophrenia a Progressive Neurodevelopmental Disorder? Toward a
Unitary Pathogenetic Mechanism. *AJP* 1998; **155**: 1661–70.

41 Haijma SV, Van Haren N, Cahn W, Koolschijn PCMP, Hulshoff Pol HE, Kahn RS. Brain
Volumes in Schizophrenia: A Meta-Analysis in Over 18 000 Subjects. *Schizophrenia Bulletin*
2013; **39**: 1129–38.

42 Gassó P, Mas S, Molina O, Bernardo M, Lafuente A, Parellada E.
Neurotoxic/neuroprotective activity of haloperidol, risperidone and paliperidone in
neuroblastoma cells. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*
2012; **36**: 71–7.

43 Fusar-Poli P, Smieskova R, Kempton MJ, Ho BC, Andreasen NC, Borgwardt S. Progressive
brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of
longitudinal MRI studies. *Neurosci Biobehav Rev* 2013; **37**: 1680–91.

44 Zipparo L, Whitford TJ, Redoblado Hodge MA, Lucas S, Farrow TFD, Brennan J, *et al.*
Investigating the neuropsychological and neuroanatomical changes that occur over the
first 2-3 years of illness in patients with first-episode schizophrenia. *Prog*
Neuropsychopharmacol Biol Psychiatry 2008; **32**: 531–8.

45 Zabala A, Eguiluz JI, Segarra R, Enjuto S, Ezcurra J, Elizagarate E, *et al.* Course of cognitive
functioning in first-episode psychosis: a comparison between schizophrenia and non
schizophrenia psychosis. *Rev Psiquiatr Salud Ment* 2008; **1**: 18–25.

46 Kawai N, Yamakawa Y, Baba A, Nemoto K, Tachikawa H, Hori T, *et al.* High-dose of multiple
antipsychotics and cognitive function in schizophrenia: The effect of dose-reduction.
Progress in Neuro-Psychopharmacology and Biological Psychiatry 2006; **30**: 1009–14.

47 Fusar-Poli P, Papanastasiou E, Stahl D, Rocchetti M, Carpenter W, Shergill S, *et al.*
Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized
Placebo-Controlled Trials. *Schizophr Bull* 2015; **41**: 892–9.

48 Austin SF, Mors O, Budtz-Jørgensen E, Secher RG, Hjorthøj CR, Bertelsen M, *et al.* Long-
term trajectories of positive and negative symptoms in first episode psychosis: A 10 year
follow-up study in the OPUS cohort. *Schizophrenia Research* 2015; **168**: 84–91.

49 Grinchii D, Dremencov E. Mechanism of Action of Atypical Antipsychotic Drugs in Mood
Disorders. *Int J Mol Sci* 2020; **21**: 9532.

50 Celada P, Puig MV, Amargós-Bosch M, Adell A, Artigas F. The therapeutic role of 5-HT1A
and 5-HT2A receptors in depression. *J Psychiatry Neurosci* 2004; **29**: 252–65.

51 Bernstein H-G, Steiner J, Guest PC, Dobrowolny H, Bogerts B. Glial cells as key players in
schizophrenia pathology: recent insights and concepts of therapy. *Schizophr Res* 2015;
161: 4–18.

52 Marek S, Tervo-Clemmens B, Calabro FJ, Montez DF, Kay BP, Hatoum AS, *et al.*
Reproducible brain-wide association studies require thousands of individuals. *Nature*
2022; **603**: 654–60.

53 Study design features increase replicability in brain-wide association studies | Nature.
(https://www.nature.com/articles/s41586-024-08260-9).

54 Maas CJM, Hox JJ. Sufficient Sample Sizes for Multilevel Modeling. *Methodology: European*
Journal of Research Methods for the Behavioral and Social Sciences 2005; **1**: 86–92.

55   Di Biase MA, Tian YE, Bethlehem RAI, Seidlitz J, Alexander-Bloch AF, Yeo BTT, *et al.*
Mapping human brain charts cross-sectionally and longitudinally. *Proc Natl Acad Sci U S A*
2023; **120**: e2216798120.

692